These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 9738557)

  • 1. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
    Koops HS; Vaglini M; Suciu S; Kroon BB; Thompson JF; Göhl J; Eggermont AM; Di Filippo F; Krementz ET; Ruiter D; Lejeune FJ
    J Clin Oncol; 1998 Sep; 16(9):2906-12. PubMed ID: 9738557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
    Olofsson Bagge R; Mattsson J; Hafström L
    Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion in primary and recurrent melanoma: indications and results.
    Liénard D; Eggermont AM; Kroon BB; Schraffordt Koops H; Lejeune FJ
    Semin Surg Oncol; 1998; 14(3):202-9. PubMed ID: 9548602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
    Olofsson R; Mattsson J; Lindnér P
    Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra HJ; Veerman K; van Ginkel RJ
    J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
    Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
    Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion.
    Bagge AS; Ben-Shabat I; Belgrano V; Olofsson Bagge R
    Ann Surg Oncol; 2016 Jun; 23(6):2062-9. PubMed ID: 26868956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
    Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
    Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
    Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
    Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
    Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
    Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Hart GA; Kroon BB
    Ann Surg Oncol; 2004 May; 11(5):491-9. PubMed ID: 15078633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.
    Belgrano V; Pettersson J; Nilsson JA; Mattsson J; Katsarelias D; Olofsson Bagge R
    Ann Surg Oncol; 2019 Apr; 26(4):1055-1062. PubMed ID: 30617871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.
    Sanki A; Kam PC; Thompson JF
    Ann Surg; 2007 Apr; 245(4):591-6. PubMed ID: 17414608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.